Log In
BCIQ
Print this Print this
 

KY1005

  Manage Alerts
Collapse Summary General Information
Company Kymab Group Ltd.
DescriptionAnti-OX40L mAb
Molecular Target OX40 ligand (OX40L) (CD134L)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationGraft-versus-host disease (GvHD)
Indication DetailsTreat Graft-versus-host disease (GvHD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today